Nimotop S (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in vascular smooth‑muscle and neuronal cells. This inhibition reduces calcium entry, causing dilation of cerebral arteries, enhancing cerebral perfusion, and providing neuroprotective effects that limit calcium‑mediated neuronal injury.

The appropriate dose of Nimotop S is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Nimotop S product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nimodipine is a dihydropyridine calcium‑channel blocker with a high affinity for cerebral vessels, offering both vasodilation and neuroprotection. Compared with non‑selective vasodilators, it provides targeted cerebral effects while minimizing systemic hypotension, making it the preferred choice for subarachnoid hemorrhage‑related vasospasm.

Nimotop S should be stored at ambient temperature below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Nimotop S is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless otherwise directed by a healthcare professional. Administration timing and frequency are set by the prescribing clinician.

The most serious risks include severe hypotension, myocardial infarction, hepatic dysfunction, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these events, and any sudden changes in blood pressure or liver function should prompt immediate medical evaluation.

Nimotop S is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. It should also be avoided in individuals with severe uncontrolled hypotension or in whom the risks of vasodilation outweigh potential benefits, as determined by a physician.